Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD
Target Price
The average target price of ACAD is 29 and suggests 33% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell